Download
s00345-021-03628-2.pdf 756,59KB
WeightNameValue
1000 Titel
  • Predictive value of De Ritis ratio in metastatic renal cell carcinoma treated with tyrosine-kinase inhibitors
1000 Autor/in
  1. Janisch, Florian |
  2. Klotzbücher, Thomas |
  3. Marks, Phillip |
  4. Kienapfel, Christina |
  5. Meyer, Christian P. |
  6. Yu, Hang |
  7. Fühner, Constantin |
  8. Hillemacher, Tobias |
  9. Mori, Keiichiro |
  10. Mostafei, Hadi |
  11. Shariat, Shahrokh F. |
  12. Fisch, Margit |
  13. Dahlem, Roland |
  14. Rink, Michael |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-03-01
1000 Erschienen in
1000 Quellenangabe
  • 39(8):2977-2985
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00345-021-03628-2 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8405478/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Background!#!Predictive markers can help tailor treatment to the individual in metastatic renal cell carcinoma (mRCC). De Ritis ratio (DRR) is associated with oncologic outcomes in various solid tumors.!##!Objective!#!To assess the value of DRR in prognosticating survival in mRCC patients treated with tyrosine-kinase inhibitors (TKI).!##!Methods!#!Overall, 220 mRCC patients treated with TKI first-line therapy were analyzed. An optimal cut-off point for DRR was determined with Youden's J. We used multiple strata for DRR, performed descriptive, Kaplan-Meier and multivariable Cox-regression analyses to assess associations of DRR with progression-free (PFS) and overall survival (OS).!##!Results!#!Patients above the optimal cut-off point for DRR of ≥ 1.58 had fewer liver metastases (p = 0.01). There was no difference in PFS (p > 0.05) between DRR groups. DRR above the median of 1.08 (HR 1.42; p = 0.03), DRR ≥ 1.1(HR 1.44; p = 0.02), ≥ 1.8 (HR 1.56; p = 0.03), ≥ 1.9 (HR 1.59; p = 0.02) and ≥ 2.0 (HR 1.63; p = 0.047) were associated with worse OS. These associations did not remain after multivariable adjustment. In the intermediate MSKCC group, DRR was associated with inferior OS at cut-offs ≥ 1.0 (HR 1.78; p = 0.02), ≥ 1.1 (HR 1.81; p = 0.01) and above median (HR 1.88; p = 0.007) in multivariable analyses. In patients with clear-cell histology, DRR above median (HR 1.54; p = 0.029) and DRR ≥ 1.1 (HR 1.53; p = 0.029) were associated with OS in multivariable analyses.!##!Conclusion!#!There was no independent association between DRR and survival of mRCC patients treated with TKI in the entire cohort. However, OS of patients with intermediate risk and clear-cell histology were affected by DRR. DRR could be used for tailored decision-making in these subgroups.
1000 Sacherschließung
lokal Aspartate Aminotransferases/analysis [MeSH]
lokal Neoplasm Grading [MeSH]
lokal Sorafenib/administration
lokal Cytoreduction Surgical Procedures/methods [MeSH]
lokal Alanine Transaminase/blood [MeSH]
lokal De ritis ratio
lokal Kidney Neoplasms/pathology [MeSH]
lokal Sulfonamides/adverse effects [MeSH]
lokal Original Article
lokal Neoplasm Staging [MeSH]
lokal Nephrectomy/methods [MeSH]
lokal Male [MeSH]
lokal Tumor markers
lokal Metastatic renal cell carcinoma
lokal Sunitinib/administration
lokal Carcinoma, Renal Cell/blood [MeSH]
lokal Karnofsky Performance Status [MeSH]
lokal Protein Kinase Inhibitors/adverse effects [MeSH]
lokal Aspartate Aminotransferases/blood [MeSH]
lokal Female [MeSH]
lokal Prognostic marker
lokal Alanine Transaminase/analysis [MeSH]
lokal Humans [MeSH]
lokal Protein Kinase Inhibitors/administration
lokal Kidney Neoplasms/surgery [MeSH]
lokal Sorafenib/adverse effects [MeSH]
lokal Survival Analysis [MeSH]
lokal Predictive Value of Tests [MeSH]
lokal Pyrimidines/administration
lokal Middle Aged [MeSH]
lokal Kidney Neoplasms/blood [MeSH]
lokal Sulfonamides/administration
lokal Tyrosine-kinase inhibitors
lokal Indazoles/administration
lokal Kidney Neoplasms/drug therapy [MeSH]
lokal Carcinoma, Renal Cell/drug therapy [MeSH]
lokal Prognosis [MeSH]
lokal Pyrimidines/adverse effects [MeSH]
lokal Indazoles/adverse effects [MeSH]
lokal Sunitinib/adverse effects [MeSH]
lokal Carcinoma, Renal Cell/pathology [MeSH]
lokal Carcinoma, Renal Cell/surgery [MeSH]
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0003-0517-0482|https://frl.publisso.de/adhoc/uri/S2xvdHpiw7xjaGVyLCBUaG9tYXM=|https://frl.publisso.de/adhoc/uri/TWFya3MsIFBoaWxsaXA=|https://frl.publisso.de/adhoc/uri/S2llbmFwZmVsLCBDaHJpc3RpbmE=|https://frl.publisso.de/adhoc/uri/TWV5ZXIsIENocmlzdGlhbiBQLg==|https://frl.publisso.de/adhoc/uri/WXUsIEhhbmc=|https://frl.publisso.de/adhoc/uri/RsO8aG5lciwgQ29uc3RhbnRpbg==|https://frl.publisso.de/adhoc/uri/SGlsbGVtYWNoZXIsIFRvYmlhcw==|https://frl.publisso.de/adhoc/uri/TW9yaSwgS2VpaWNoaXJv|https://frl.publisso.de/adhoc/uri/TW9zdGFmZWksIEhhZGk=|https://frl.publisso.de/adhoc/uri/U2hhcmlhdCwgU2hhaHJva2ggRi4=|https://frl.publisso.de/adhoc/uri/RmlzY2gsIE1hcmdpdA==|https://frl.publisso.de/adhoc/uri/RGFobGVtLCBSb2xhbmQ=|https://frl.publisso.de/adhoc/uri/UmluaywgTWljaGFlbA==
1000 Hinweis
  • DeepGreen-ID: 993d5639ced744029b22d6e8374b46d2 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6451125.rdf
1000 Erstellt am 2023-05-11T12:17:06.504+0200
1000 Erstellt von 322
1000 beschreibt frl:6451125
1000 Zuletzt bearbeitet 2023-10-21T04:20:47.733+0200
1000 Objekt bearb. Sat Oct 21 04:20:47 CEST 2023
1000 Vgl. frl:6451125
1000 Oai Id
  1. oai:frl.publisso.de:frl:6451125 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source